The main department of described VC is located in the Seoul. The venture was found in Asia in South Korea. Medivate Partners seemed to be an CVC arrangement as part of the organization.
The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Medivate Partners, startups are often financed by Tennenbaum Capital Partners, Scott H. Cohen, EW Healthcare Partners. The meaningful sponsors for the fund in investment in the same round are Tennenbaum Capital Partners, Qiming Venture Partners, FoxKiser. In the next rounds fund is usually obtained by EW Healthcare Partners.
Among the most popular portfolio startups of the fund, we may highlight SillaJen, WindMIL Therapeutics. We can highlight the next thriving fund investment areas, such as Medical, Manufacturing. The fund has no specific favorite in a number of founders of portfolio startups. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.
The higher amount of exits for fund were in 2016. This Medivate Partners works on 4 percentage points more the average amount of lead investments comparing to the other organizations. The high activity for fund was in 2018. Considering the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in less than 2 investment rounds annually.
Related Funds
Funds with similar focus
Fund Name | Location |
Alafi Capital | California, San Francisco, United States |
AVAC | Alberta, Calgary, Canada |
Blinc Advisors | - |
G2link | China, Shanghai |
Interplay Ventures | New York, New York, United States |
J.F. Lehman & Co | New York, New York, United States |
Thalys Medical Group | - |
Tier 1 banks | - |
Timeline Investment | Ajax, Canada, Ontario |
Yuanshengbei Chuang | China, Huaihua, Hunan |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Cipherome | $16K | 14 Feb 2022 | San Jose, California, United States | ||
SoVarGen | $30M | 10 Sep 2020 | Daejeon, Taejon-jikhalsi, South Korea | ||
Artiva Biotherapeutics | $78M | 26 Jun 2020 | San Diego, California, United States | ||
Cognate BioServices | 21 Jan 2020 | Maryland, United States | |||
WindMIL Therapeutics | $32M | 18 Jun 2018 | New Jersey, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Cipherome | $16K | 14 Feb 2022 | San Jose, California, United States | ||
SoVarGen | $30M | 10 Sep 2020 | Daejeon, Taejon-jikhalsi, South Korea | ||
Artiva Biotherapeutics | $78M | 26 Jun 2020 | San Diego, California, United States | ||
Cognate BioServices | 21 Jan 2020 | Maryland, United States | |||
WindMIL Therapeutics | $32M | 18 Jun 2018 | New Jersey, United States |